Profile data is unavailable for this security.
About the company
Bioporto A/S is a Denmark-based company engaged in the development and marketing of in vitro diagnostic (IVD) assays. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.
- Revenue in DKK (TTM)30.96m
- Net income in DKK-56.33m
- Incorporated1917
- Employees31.00
- LocationBioporto A/STuborg Havnevej 15, St.HELLERUP 2900DenmarkDNK
- Phone+45 45290000
- Fax+45 45290001
- Websitehttps://bioporto.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lifecare AS | 8.30m | -22.36m | 291.27m | 32.00 | -- | 6.92 | -- | 35.09 | -0.2903 | -0.2903 | 0.1088 | 0.4924 | 0.1621 | -- | 4.90 | 408,943.10 | -43.60 | -40.00 | -49.97 | -45.26 | -- | -- | -269.03 | -175.53 | -- | -- | 0.1812 | -- | -40.88 | 30.29 | -101.74 | -- | -- | -- |
| Initiator Pharma A/S | 0.00 | -22.87m | 304.95m | 3.00 | -- | 27.09 | -- | -- | -0.6567 | -0.6567 | 0.00 | 0.3319 | 0.00 | -- | -- | 0.00 | -58.55 | -65.10 | -62.50 | -70.59 | -- | -- | -- | -- | -- | -- | 0.5804 | -- | -- | -- | 40.52 | -- | -- | -- |
| Mendus AB (publ) | 0.00 | -65.12m | 316.26m | 30.00 | -- | 0.6002 | -- | -- | -0.2554 | -0.2554 | 0.00 | 0.8165 | 0.00 | -- | -- | 0.00 | -14.77 | -18.84 | -15.78 | -20.21 | -- | -- | -- | -28,474.53 | -- | -- | 0.0325 | -- | -100.00 | -- | 26.78 | -- | -- | -- |
| Promimic AB | 23.75m | -5.91m | 346.72m | 17.00 | -- | 7.05 | -- | 14.60 | -0.5295 | -0.5295 | 2.08 | 4.11 | 0.3994 | -5.63 | 3.00 | 2,180,588.00 | -9.93 | -24.88 | -11.67 | -29.25 | 103.90 | 101.23 | -24.87 | -89.46 | 3.98 | -- | -- | -- | 128.63 | -- | 41.95 | -- | -- | -- |
| IRLAB Therapeutics AB | 3.64m | -113.96m | 350.12m | 37.00 | -- | 4.73 | -- | 96.23 | -3.43 | -3.43 | 0.1095 | 2.23 | 0.0227 | -- | 0.5137 | -- | -71.04 | -27.12 | -82.41 | -30.42 | -2,161.57 | -72.18 | -3,132.07 | -155.57 | -- | -- | 0.1923 | -- | -90.71 | 216.07 | -56.82 | -- | -22.56 | -- |
| Gentian Diagnostics ASA | 85.72m | -6.75m | 367.80m | 58.00 | -- | 3.95 | -- | 4.29 | -0.6905 | -0.6905 | 8.76 | 9.51 | 0.7329 | 1.76 | 7.47 | 2,330,224.00 | -5.77 | -10.76 | -6.62 | -11.86 | 50.61 | 41.46 | -7.88 | -26.99 | 4.13 | -- | 0.0817 | -- | 32.98 | 27.63 | 54.92 | -- | -4.92 | -- |
| Orexo AB | 409.22m | -82.28m | 378.13m | 116.00 | -- | 9.94 | -- | 0.924 | -3.73 | -3.73 | 18.55 | 1.71 | 0.6738 | 1.52 | 2.88 | 5,505,173.00 | -13.55 | -6.41 | -20.60 | -9.99 | 86.09 | 86.76 | -20.11 | -11.83 | 1.58 | 0.3604 | 0.8894 | -- | 2.32 | -3.99 | 27.76 | -- | 25.77 | -- |
| Enzymatica AB (publ) | 32.62m | -31.87m | 392.20m | 21.00 | -- | 7.57 | -- | 12.02 | -0.3027 | -0.3027 | 0.3099 | 0.4664 | 0.339 | 1.66 | 3.98 | -- | -33.12 | -27.36 | -35.04 | -33.98 | 62.59 | 65.08 | -97.69 | -66.12 | -- | -26.45 | 0.1909 | -- | 4.00 | -0.6382 | 27.57 | -- | 7.02 | -- |
| Cantargia AB | 0.00 | -179.44m | 420.22m | 22.00 | -- | 3.89 | -- | -- | -1.65 | -1.65 | 0.00 | 0.9186 | 0.00 | -- | -- | 0.00 | -80.18 | -55.08 | -100.27 | -61.35 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 24.69 | -- | -- | -- |
| Oncopeptides AB | 22.57m | -159.63m | 435.43m | 57.00 | -- | 7.20 | -- | 19.29 | -1.97 | -1.97 | 0.278 | 0.4474 | 0.1129 | -- | 1.51 | 617,894.80 | -79.88 | -141.28 | -101.04 | -200.49 | 103.06 | -- | -707.30 | -2,689.06 | 4.46 | -- | 0.7065 | -- | 321.54 | -- | 26.29 | -- | -- | -- |
| Alligator Bioscience AB | 37.24m | -159.30m | 446.90m | 58.00 | -- | 51.13 | -- | 12.00 | -0.5613 | -0.5613 | 0.1205 | 0.018 | 0.4035 | -- | 8.34 | 1,001,845.00 | -172.61 | -73.26 | -399.57 | -91.33 | -- | -- | -427.81 | -811.68 | -- | -- | 0.5759 | -- | 62.78 | 16.60 | -28.53 | -- | -20.34 | -- |
| Intellego Technologies AB | 119.51m | 38.20m | 466.08m | 68.00 | 11.68 | 4.81 | 11.52 | 3.90 | 2.36 | 2.36 | 7.43 | 5.74 | 0.8841 | 3.26 | 3.69 | 2,742,544.00 | 28.26 | -- | 44.00 | -- | 68.73 | -- | 31.96 | -- | 1.97 | 5.82 | 0.1684 | -- | 222.74 | -- | 493.56 | -- | -- | -- |
| BioPorto A/S | 30.96m | -56.33m | 466.24m | 31.00 | -- | 7.75 | -- | 15.06 | -0.1605 | -0.1605 | 0.0883 | 0.1585 | 0.312 | 3.40 | 11.96 | 998,645.20 | -56.77 | -71.10 | -79.27 | -96.55 | 65.19 | 63.38 | -181.95 | -239.22 | 3.09 | -1,718.97 | 0.1076 | -- | 6.87 | 3.54 | 25.81 | -- | -51.56 | -- |
| Nightingale Health Oyj | 27.25m | -134.69m | 497.46m | 81.00 | -- | 1.14 | -- | 18.25 | -0.2979 | -0.2979 | 0.0603 | 1.50 | 0.0344 | 1.60 | 3.87 | 44,560.98 | -17.02 | -14.20 | -18.12 | -15.69 | 75.81 | 83.57 | -494.25 | -408.50 | 14.15 | -- | 0.0378 | -- | 80.80 | 19.05 | -12.38 | -- | -- | -- |
| Moberg Pharma AB (publ) | 0.00 | -13.52m | 628.03m | -- | -- | 1.58 | -- | -- | -1.20 | -1.20 | 0.00 | 21.84 | 0.00 | -- | -- | -- | -3.52 | -- | -3.66 | -- | -- | -- | -- | -- | 3.04 | -- | 0.0077 | -- | -100.00 | -- | -34.26 | -- | -- | -- |
Data as of Apr 25 2024. Currency figures normalised to Bioporto A/S's reporting currency: Danish Krone DKK
0.23%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Danske Bank A/S (Investment Management)as of 31 Jan 2024 | 625.55k | 0.17% |
| Dimensional Fund Advisors Ltd.as of 29 Feb 2024 | 110.66k | 0.03% |
| Dimensional Fund Advisors LPas of 04 Apr 2024 | 73.51k | 0.02% |
| Sydbank A/S (Investment Management)as of 27 Mar 2024 | 48.08k | 0.01% |
More ▼
Data from 31 Dec 2023 - 18 Apr 2024Source: FactSet Research Systems Inc.
